Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Soligenix, Inc. - Common Stock (NQ:SNGX)

2.940 +0.490 (+20.00%)
Streaming Delayed Price Updated: 4:00 PM EDT, Aug 14, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Soligenix, Inc. - Common Stock

< Previous 1 2 3 4 Next >
BioMedNewsBreaks – Soligenix Inc. (NASDAQ: SNGX) Q2 2025 Results Highlight Progress in Late-Stage Rare Disease Pipeline
Via Investor Brand Network
InvestorNewsBreaks – Alliance Global Partners Maintains Buy Rating, Increases Price Target as Soligenix Inc. (NASDAQ: SNGX) Advances Proprietary Clinical Programs
Via Investor Brand Network
BioMedNewsBreaks — Soligenix Inc. (NASDAQ: SNGX) Featured in NNW Editorial on Rare Disease Innovation
Via Investor Brand Network
Soligenix Inc. (NASDAQ: SNGX) Proprietary Platform Aims to Meet Growing Need for Effective CTCL Therapy
From Soligenix, Inc.
Via GlobeNewswire
Clinical Progress in Rare Disease Signals Long-Term Revenue Potential for Innovators
Via Investor Brand Network
Topics Government
Clinical Progress in Rare Disease Signals Long-Term Revenue Potential for Innovators
EQNX::TICKER_START (NASDAQ:SNGX),(NASDAQ:FOLD),(NASDAQ:TNXP),(NASDAQ:CTOR),(NASDAQ:AMGN) EQNX::TICKER_END 
Via FinancialNewsMedia
Topics Government
BioMedNewsBreaks — Soligenix Inc. (NASDAQ: SNGX) Spotlighted in Editorial on Rare Disease Therapeutics
Via Investor Brand Network
Study Finds That Inflammation Markers in Diabetics Influence Depression Treatment Outcomes
Via Investor Brand Network
Soligenix Inc. (NASDAQ: SNGX) Innovative Platform Provides Novel Treatment for Underserved CTCL Space
From Soligenix, Inc.
Via GlobeNewswire
Late-Stage Pipeline Wins Boost Investor Confidence in High-Growth Therapeutic Areas
Via Investor Brand Network
Topics Government
Late-Stage Pipeline Wins Boost Investor Confidence in High-Growth Therapeutic Areas
EQNX::TICKER_START (NASDAQ:SNGX),(NYSE:PFE),(NYSE:MRK),(NYSE:BMY),(NASDAQ:INSM) EQNX::TICKER_END 
Via FinancialNewsMedia
Topics Government
Loop Industries (Nasdaq: LOOP) Unveils Game-Changing Twist™ Polyester Made Entirely from Textile Waste – More Stocks Inside
Via AB Newswire
Topics Economy Emissions Energy
InvestorNewsBreaks – Soligenix Inc. (NASDAQ: SNGX) Achieves Biological Efficacy in Phase 2a SGX945 Study for Behçet’s Disease
Via Investor Brand Network
BioMedNewsBreaks — Targeting the Unmet: Soligenix Inc. (NASDAQ: SNGX) Building Portfolio for Rare Conditions
Via Investor Brand Network
Soligenix Inc. (NASDAQ: SNGX) Pioneering Oral Mucositis Treatment with Novel Therapeutic, Promising Study Results
Via Investor Brand Network
Global Vaccination Goals at Risk as 14 Million Kids Miss Crucial Shots
Via Investor Brand Network
Soligenix Inc. (NASDAQ: SNGX) Reports Strong Results in ‘Real-World’ Trial
Via Investor Brand Network
InvestorNewsBreaks – Zacks Research Releases Updated Report as Soligenix Inc. (NASDAQ: SNGX) Eyes Upcoming ‘Key Catalysts’
Via Investor Brand Network
Dutch Startup Develops Highly Sensitive Field Test for Infectious Diseases
Via Investor Brand Network
Topics Climate Change
BioMedNewsBreaks – Soligenix Inc. (NASDAQ: SNGX) Targets Multiple 2025–2026 Catalysts Across Rare Disease Pipeline
Via Investor Brand Network
Soligenix Inc. (NASDAQ: SNGX) Highlights Encouraging Phase 3 Progress for HyBryte(TM) in Investment Webinar
Via Investor Brand Network
Research Finds That Pesticides Disrupt Inflammation-Linked Bacteria
Via Investor Brand Network
InvestorNewsBreaks – Soligenix Inc. (NASDAQ: SNGX) Advancing Novel Immunotherapy to Combat Antibiotic Resistance
Via Investor Brand Network
Soligenix Inc. (NASDAQ: SNGX) Proprietary Therapy Shows Promise in Treatment of Psoriasis
Via Investor Brand Network
Study Finds the Overall Prevalence of Psoriasis in the US Unchanged
Via Investor Brand Network
Soligenix Inc. (NASDAQ: SNGX) Makes Advancement in Proprietary Treatment for Behçet’s Disease
Via Investor Brand Network
InvestorNewsBreaks – Soligenix Inc. (NASDAQ: SNGX) Advances Clinical Programs, Eyes Critical Trial Results in 2025–2026
Via Investor Brand Network
Soligenix Inc. (NASDAQ: SNGX) Offers Hope on the Horizon with HyBryte(TM) Treatment Targeting CTCL
Via Investor Brand Network
Therapeutic Target Shows Promise in Preventing Cancer Resulting from Chronic Gut Inflammation
Via Investor Brand Network
BioMedNewsBreaks — Soligenix Inc. (SNGX) Highlights HyBryte Progress in CTCL via New Podcast Featuring Dr. Ellen Kim
Via Investor Brand Network
< Previous 1 2 3 4 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.